Additionally "For over a year now there has been ever growing, extensive, and overwhelming clinical evidence that HCQ, when used within the first five days of symptom onset, produces a sharp and statistically significant reduction in COVID hospitalization and mortality. Adverse cardiac events are not a factor.
By July of 2020, seven controlled, well-conducted clinical studies had been conducted in Brazil (1353 patients); France (425 nursing-home and clinic patients); New Jersey (1,247 outpatients); Andorra (100 long-term care patients); and 7,892 patients across Saudi Arabia. All of these studies used the premise of the early treatment of high-risk mortality COVID outpatients, and all showed 50% or higher reductions in hospitalization and death. Not a single fatal cardiac arrhythmia was attributable to HCQ in over 11,000 outpatient outcomes. 14
In addition, a summary analysis of five randomized controlled clinical trials involving 5,577 patients in the United States and Spain, also found that outpatient use of HCQ for early treatment of COVID-19, significantly reduced the composite of hospitalization and death. 15 Again, adverse cardiac events were not a factor." See https://drstevenhatfill.com/how-a-single-point-failure-destroyed-the-national-pandemic-plan/
Our own government "refused to publish the ground-breaking June 2020 study showing that early HCQ hospital use is associated with a 51% reduction in mortality. These results were quickly reproduced by a Mt Sinai study and by a later Spanish study which showed a 66% reduction in COVID mortality." See https://drstevenhatfill.com/how-a-single-point-failure-destroyed-the-national-pandemic-plan/
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.